Baird Medical Investment Holdings Ltd. commenced trading on the Nasdaq exchange under the ticker symbol "BDMD" on October 2, 2024. This milestone followed the successful closure of its business combination with ExcelFin Acquisition Corp., marking the company's official entry into the U.S. public market.
The Nasdaq listing is a critical juncture for Baird Medical, signifying its strategic shift towards addressing unmet needs in the U.S. market. This move follows the company's recent FDA clearance for its minimally invasive microwave ablation technology.
Baird Medical's technology offers a promising alternative to traditional thyroidectomy for patients with benign thyroid tumors. Approximately 150,000 thyroidectomies are performed annually in the U.S., indicating a substantial market opportunity for the company's innovative solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.